About Us.
"JUNG&JI Nonclinical Consulting do not claim to be the 'best,' but we promise to do our 'best' for you."
"Nonclinical is a web, not a line ."
In this complex web, we know how easy it is to feel lost. At JJNC, we understand the weight of anxiety and hope that every new drug carries. That is why we go beyond analyzing data; we analyze your concerns and think through them together. We value Sincerity over speed and Partnership over prestige. We exist to be the steady companion who shares your burden and navigates the rough terrain with you. We may not be the largest firm, but we are the partner who will worry with you and work the hardest for your success
ANDREW (SOOYONG) JUNG
CHIEF EXECUTIVE OFFICER
Andrew serves as the Chief Scientific Officer (CSO) at AIMS BioScience, bringing extensive expertise in DMPK, in vivo toxicology, and pharmacology. With a distinguished career spanning major pharmaceutical companies such as LG Life Sciences and Yuhan Corporation, he has played a pivotal role in drug development strategies. Andrew has successfully contributed to six global licensing-out deals and has provided expert consulting for numerous Phase 1 IND approvals.
KATE SUNG MI JI
VICE PRESIDENT
Kate is a seasoned Project Management expert and Senior Consultant at AIMS BioScience, specializing in both non-clinical and clinical sectors. Holding international certifications in project management (PMP, PRINCE2), she has successfully managed over 100 projects. With a strong background in global business development at companies like Orient Bio and Seoulin Bioscience, Kate possesses exceptional expertise in establishing robust CRO networks and verifying CRO capabilities for global nonclinical studies.